ReviewOncotarget2017

Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature.

Ryobu Mori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.